Abbott has developed two types of implantable neurostimulation devices that employ two advanced spinal column stimulation (SCS) techniques, respectively, dorsal root ganglion (DRG) stimulation and Abbott’s proprietary BURSTDR™ stimulation. Both types of SCS neuromodulation may be superior to conventional tonic spinal cord therapy (cSCS) used in clinical practice for the last several decades. The devices have long-lasting batteries and are able to receive software upgrades while implanted.

In the ACCURATE clinical trial, DRG stimulation was successful in confining the sensation of paresthesia to the primary area of pain in over 90 percent of patients with chronic regional pain syndrome (CRPS).1

According to Hunter et al, published January 2019 in Neuromodulation, “DRGS can be an effective treatment for a variety of neuropathic pain syndromes, in addition to CRPS.”


Allen W. Burton, MD
Medical Director, Neuromodulation at Abbott

  1. Deer T, Levy M, Kramer J, et al. Dorsal root ganglion stimulation yielded higher treatment success rate for complex regional pain syndrome and causalgia at 3 and 12 months: a randomized comparative trial. Pain. 2017;158(4):669-681.